Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stoccolma | Salute | Ricerca medica e biotecnologica | 15,88 Mrd SEK | -68,4x | 0,36 | 179,60 SEK | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioinvent | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,69 Mrd SEK | -6,6x | 0,23 | 40,90 SEK | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Egetis Therapeutics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,39 Mrd SEK | -6x | -0,33 | 6,58 SEK | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hansa Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,08 Mrd SEK | -2,8x | -0,1 | 30,60 SEK | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Devyser Diagnostics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,01 Mrd SEK | -30,8x | 1,25 | 122 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 25,7% Rialzo | Fai l’upgrade a Pro+ | |
Vicore Pharma Holding AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,84 Mrd SEK | -4,4x | -0,22 | 7,83 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Diamyd Medical | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,61 Mrd SEK | -9,7x | 1,27 | 15,36 SEK | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cereno Scientific | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,57 Mrd SEK | -20,9x | 0,41 | 5,56 SEK | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
XSpray Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,50 Mrd SEK | -5,7x | 1,21 | 44,55 SEK | -1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nanoform Finland Plc | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,30 Mrd SEK | -4,9x | 1,7 | 15 SEK | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Intellego Technologies AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,19 Mrd SEK | 13,8x | 0,16 | 41,05 SEK | -3,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nykode Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 916,33 Mln SEK | -1,9x | 13,98 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Saniona AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 733,97 Mln SEK | -7,6x | -0,35 | 6,56 SEK | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -8,1% Ribasso | Fai l’upgrade a Pro+ | |
Hamlet Pharma AB | Spotlight | Salute | Ricerca medica e biotecnologica | 578,78 Mln SEK | -14,2x | 0,74 | 3,49 SEK | 3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Promimic AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 492,55 Mln SEK | -48,5x | 2,66 | 26 SEK | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
SynAct Pharma AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 450,96 Mln SEK | -2,1x | -0,14 | 11,04 SEK | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 49,5% Rialzo | Fai l’upgrade a Pro+ | |
Mendus AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 444,02 Mln SEK | -3,1x | -0,06 | 8,82 SEK | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Initiator Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 399,33 Mln SEK | -23,6x | -0,39 | 7,10 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Peptonic Medical | Spotlight | Salute | Ricerca medica e biotecnologica | 345,56 Mln SEK | -0,4x | -0,01 | 0,004 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Oncopeptides | Stoccolma | Salute | Ricerca medica e biotecnologica | 331,39 Mln SEK | -0,8x | -0,04 | 1,55 SEK | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alzinova | Stoccolma | Salute | Ricerca medica e biotecnologica | 329,91 Mln SEK | -10,9x | -0,75 | 3,70 SEK | -2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cantargia AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 326,96 Mln SEK | -1,7x | -0,04 | 1,79 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curasight AS | Spotlight | Salute | Ricerca medica e biotecnologica | 326,79 Mln SEK | -7,2x | 0,51 | 17,66 SEK | 11,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Ascelia Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 307,54 Mln SEK | -2x | -0,07 | 3,24 SEK | 2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medivir | Stoccolma | Salute | Ricerca medica e biotecnologica | 301,73 Mln SEK | -0,09 | 2,65 SEK | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Xbrane Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 260,01 Mln SEK | -0,4x | -0,01 | 0,17 SEK | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Biovica International | Stoccolma | Salute | Ricerca medica e biotecnologica | 258,84 Mln SEK | -1,7x | -0,05 | 2,87 SEK | 7,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Guard Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 232,37 Mln SEK | -2,3x | -0,07 | 19,20 SEK | -4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abliva AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 225,66 Mln SEK | -1,9x | -0,19 | 0,14 SEK | -3,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alligator Bioscience | Stoccolma | Salute | Ricerca medica e biotecnologica | 225,14 Mln SEK | -0,9x | -0,02 | 0,30 SEK | -3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |